Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: early-phase trial registry
2 of 10 indexed Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: 10 US clinical trials tracked, 2 recruiting.
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition accelerated-phase-chronic-myelogenous-leukemia-bcr-abl1-positive
OPEN 2 | RECR 20% | LATE 0 | EARLY 10 | RANK #1724 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is recruiting below its size-band peers.
2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research.
M.D. Anderson Cancer Center accounts for 7 of 10 trials (70%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials plan to enrol fewer than 100 people.
Median target enrolment is 88 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
NCT02727803
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03263572
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01424982
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03147612
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT04188405
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00105001
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01904136
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
NCT01428635
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive page
10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive condition card totals 10 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.